Bellevue Group’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-14,300
| Closed | -$2.63M | – | 227 |
|
|
2021
Q2 | $2.63M | Sell |
14,300
-1,294,428
| -99% | -$222M | 0.03% | 139 |
|
|
2021
Q1 | $200M | Sell |
1,308,728
-84,300
| -6% | -$13M | 2.12% | 9 |
|
|
2020
Q4 | $218M | Sell |
1,393,028
-28,100
| -2% | -$3.61M | 2.49% | 7 |
|
|
2020
Q3 | $163M | Buy |
1,421,128
+8,300
| +0.6% | +$895K | 2.25% | 9 |
|
|
2020
Q2 | $159M | Buy |
1,412,828
+81,500
| +6% | +$8.65M | 2.24% | 11 |
|
|
2020
Q1 | $120M | Sell |
1,331,328
-57,600
| -4% | -$5.65M | 2.32% | 10 |
|
|
2019
Q4 | $150M | Buy |
1,388,928
+22,400
| +2% | +$2.4M | 2.38% | 9 |
|
|
2019
Q3 | $134M | Buy |
1,366,528
+25,100
| +2% | +$2.83M | 2.49% | 9 |
|
|
2019
Q2 | $176M | Buy |
1,341,428
+1,170,278
| +684% | +$151M | 3% | 7 |
|
|
2019
Q1 | $23.1M | Buy |
171,150
+15,470
| +10% | +$1.92M | 1.27% | 23 |
|
|
2018
Q4 | $15.2M | Sell |
155,680
-27,400
| -15% | -$3.24M | 1.04% | 31 |
|
|
2018
Q3 | $25.4M | Buy |
183,080
+19,350
| +12% | +$2.43M | 1.61% | 18 |
|
|
2018
Q2 | $20.3M | Buy |
163,730
+32,340
| +25% | +$3.78M | 1.73% | 18 |
|
|
2018
Q1 | $14.6M | Buy |
131,390
+620
| +0.5% | +$74.1K | 1.45% | 22 |
|
|
2017
Q4 | $15.6M | Buy |
130,770
+44,770
| +52% | +$5.45M | 1.63% | 19 |
|
|
2017
Q3 | $12.1M | Sell |
86,000
-6,000
| -7% | -$815K | 1.26% | 27 |
|
|
2017
Q2 | $11.2M | Buy |
92,000
+21,000
| +30% | +$2.44M | 1.32% | 29 |
|
|
2017
Q1 | $8.61M | Buy |
71,000
+21,600
| +44% | +$2.78M | 1.15% | 33 |
|
|
2016
Q4 | $6.04M | Hold |
49,400
| – | – | 1.24% | 26 |
|
|
2016
Q3 | $6.05M | Hold |
49,400
| – | – | 1.09% | 33 |
|
|
2016
Q2 | $5.77M | Hold |
49,400
| – | – | 1.09% | 32 |
|
|
2016
Q1 | $6.88M | Buy |
+49,400
| New | +$7.25M | 1.25% | 22 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM